# A Phase 1, Open-Label, Single-photon Emission Computed Tomography (SPECT) Study to Evaluate Serotonin and Dopamine Transporter Occupancy After Multiple Dose Administration of SEP-228432 to Achieve Steady State in Healthy Subjects

> **NCT01531972** · PHASE1 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 30 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** SEP-228432
- **DRUG:** SEP-228432

## Key facts

- **NCT ID:** NCT01531972
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2013-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01531972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01531972, "A Phase 1, Open-Label, Single-photon Emission Computed Tomography (SPECT) Study to Evaluate Serotonin and Dopamine Transporter Occupancy After Multiple Dose Administration of SEP-228432 to Achieve Steady State in Healthy Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01531972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*